Ocular Therapeutix Reports Q2 Results, Confirms Q4 AXPAXLI NDA Submission, Extends Cash Runway into 2028
OCUL sits 33% above its 52-week low of $6.23.
Summary
Ocular Therapeutix reported increased Q2 net loss and cash burn but confirmed its plan to submit an NDA for AXPAXLI in wet AMD in Q4 2026, backed by a cash runway extending into 2028.
Key Events · Earnings and Guidance · OCUL
-
AXPAXLI NDA Submission Confirmed for Q4 2026
The company plans to submit a New Drug Application (NDA) to the FDA for marketing approval of AXPAXLI for wet Age-related Macular Degeneration (AMD) in the fourth quarter of 2026, following positive Phase 3 SOL-1 trial results. A pre-NDA meeting is scheduled for Q3 2026.
-
Cash Runway Extended into 2028
Ocular Therapeutix reported $598.6 million in cash and cash equivalents as of June 30, 2026, which is expected to fund planned operating expenses, debt service, and capital expenditures into 2028.
-
Increased Net Loss and Cash Burn
The net loss for the six months ended June 30, 2026, increased to $(167.4) million from $(131.9) million in the prior year. Net cash used in operating activities also increased to $(133.3) million from $(99.9) million year-over-year.
-
HELIOS-3 Trial Streamlined for Diabetic Retinopathy
The HELIOS-3 trial for diabetic retinopathy has been streamlined to a single global registrational superiority study, eliminating the 24-week dosing arm and reducing the overall subject count to approximately 620.
Analysis · OCUL · Life Sciences
This quarterly report provides a comprehensive update on Ocular Therapeutix's financial performance and critical clinical development programs. The company reported an increased net loss and cash burn, which is a negative. However, the confirmation of a Q4 2026 NDA submission for AXPAXLI in wet AMD, following positive Phase 3 results, is a major positive milestone. The company also maintains a strong cash position, extending its runway into 2028, which significantly de-risks near-term financing concerns for a clinical-stage biotech. The strategic streamlining of the HELIOS-3 trial for diabetic retinopathy also indicates focused development.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OCUL was trading at $8.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $6.23 to $16.44. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.